Category: Pharmaceuticals and Biotech
![GB Sciences Signs Letter of Intent for a License to Develop and Market Their Cannabinoid-Based Parkinson’s Formulation With Endopure Life Sciences](https://cdn.nwe.io/files/x/b8/c7/5d2c2a4a812f0b817473bf034a30.jpg)
GB Sciences’ Licensing Deal with Endopure Life Sciences will also include Rights to Develop and Market GB Sciences’ Cannabinoid-based Treatments for a Suite of Neurological Disorders
![Gb Sciences’ Novel Parkinson’s Disease Medication is Featured on Worldwide Business with kathy ireland®](https://cdn.nwe.io/files/x/55/6c/c9689b248a8302ced9405c812148.jpg)
Tune in this Sunday, Dec. 17, at 5:30 p.m. ET on the Fox Business Network to learn about Gb Sciences’ cannabinoid-based medicine for the treatment of Parkinson’s disease.
![Gb Sciences' First-in-Class Parkinson's Disease Therapy Successfully Completes Dose Response Study at the University of Lethbridge](https://cdn.nwe.io/files/x/ae/79/979e040c668e3af85786da0f5262.jpg)
The Parkinson's disease market is expected to grow to $12.8 billion by 2028.
![GB Sciences' First International Patent Protecting Its Proprietary Cannabinoid-Based Formulations for Parkinson's Disease Has Been Issued in China](https://cdn.nwe.io/files/x/c5/a6/d03b72f87ab93bd45070aea8d949.jpg)
According to Statista, China has the second largest pharmaceutical market in the world and plant-based medicines are very well accepted, which makes China a potential target market for Gb Sciences.
![Gb Sciences and Michigan State University Researchers Have Identified the Complicated Truth Behind the Opportunity for an Effective Cannabinoid-Based Coronavirus Treatment](https://cdn.nwe.io/files/x/31/ea/b3bbd744a893c346807df027298a.jpg)
Gb Sciences' collaboration with MSU has received media coverage across the country, starting with an interview from WLNS-TV in Lansing, Michigan, and interviews with Gb Sciences in the magazines 'Cannabis Business Times' and 'Hemp Grower'
![Gb Sciences Starts Preclinical Study for Plant-Based Formulas to Treat Depression and Anxiety](https://cdn.nwe.io/files/x/4b/41/9d8982cd31a7cf52bcf442a16dea.jpg)
The biopharma technology company's AI-driven PhAROS™ platform has identified novel, plant-inspired formulations that will be tested using preclinical Zebrafish models at the National Research Council of Canada.
![Gb Sciences Presenting COVID-Related Cytokine Release Syndrome Results at H.C. Wainwright's 23rd Annual Global Investment Conference](https://cdn.nwe.io/files/x/01/32/981dd6bd19c0cd1d0aeb7828b1f9.jpg)
Highlighting Gb Sciences' Development of Plant-Inspired Therapies for COVID-related Cytokine Release Syndrome, Chronic Pain, and Parkinson's Disease during the Healthcare & Biotech Track starting Monday, September 13.
![GB Sciences Using AI Technology in Plant-Based Drug Discovery Research](https://cdn.nwe.io/files/x/01/18/697d5e694df7bcc9d3366aabcec5.jpg)
Biotech innovator GB Sciences has launched a drug discovery platform using AI technology that can identify and predict the efficacy of combinations of novel active ingredients from plants.
![Gary Herman Joins GB Sciences' Subsidiary GbS Global Biopharma as Advisory Director](https://cdn.nwe.io/files/x/e1/97/ef43090e89286f7bf98282803576.jpg)
Herman will bring his experience as an investor in undervalued growth companies to this role as Advisory Director
![GB Sciences' Board of Directors Has Passed a Unanimous Written Consent Promoting Dr. Andrea Small-Howard to the Role of President](https://cdn.nwe.io/files/x/a9/71/7b0daa86afbca1ed3b7d029c7037.jpg)
The UWC also retains John Poss as Chairman and CEO of GB Sciences, Inc.
![GB Sciences Begins Proof of Concept Studies with Michigan State University for the Treatment of Cytokine Release Syndrome](https://cdn.nwe.io/files/x/e8/df/4ec3ed822d190712696d96321dca.jpg)
If successful, data from this preclinical study would be used as part of the support for an Independent New Drug (IND)-filing with the US Food and Drug Administration (FDA) for the use of GBS' Cannabinoid Containing Complex Mixtures (CCCM™) to treat the potentially-fatal Cytokine Release Syndrome associated with COVID-19 and other dangerous hyperinflammatory conditions.
This is the third U.S. patent awarded to GBS's disease-specific Cannabinoid-Containing Complex Mixtures (CCCM™), which further validates GB Sciences' drug discovery platform and strengthens its intellectual property patent portfolio